Decoding the therapeutic target SVEP1: harnessing molecular trait GWASs to unravel mechanisms of human disease

JS Elenbaas, PC Lee, V Patel… - Annual Review of …, 2025 - annualreviews.org
Although human genetics has substantial potential to illuminate novel disease pathways
and facilitate drug development, identifying causal variants and deciphering their …

[HTML][HTML] microRNAs as promising biomarkers of platelet activity in antiplatelet therapy monitoring

TL Krammer, M Mayr, M Hackl - International Journal of Molecular …, 2020 - mdpi.com
Given the high morbidity and mortality of cardiovascular diseases (CVDs), novel biomarkers
for platelet reactivity are urgently needed. Ischemic events in CVDs are causally linked to …

Ticagrelor plus aspirin versus clopidogrel plus aspirin for platelet reactivity in patients with minor stroke or transient ischaemic attack: open label, blinded endpoint …

Y Wang, W Chen, Y Lin, X Meng, G Chen, Z Wang… - bmj, 2019 - bmj.com
Objective To test the hypothesis that ticagrelor plus aspirin is safe and superior to
clopidogrel plus aspirin for reducing high platelet reactivity at 90 days and stroke recurrence …

[HTML][HTML] Genetic association study and machine learning to investigate differences in platelet reactivity in patients with acute ischemic stroke treated with aspirin

A Ikonnikova, A Anisimova, S Galkin, A Gunchenko… - Biomedicines, 2022 - mdpi.com
Aspirin resistance (AR) is a pressing problem in current ischemic stroke care. Although the
role of genetic variations is widely considered, the data still remain controversial. Our aim …

[HTML][HTML] The phenomenon of clopidogrel high on-treatment platelet reactivity in ischemic stroke subjects: a comprehensive review

A Wiśniewski, K Filipska - International journal of molecular sciences, 2020 - mdpi.com
Clopidogrel is increasingly being used for the secondary prevention of ischemic stroke
according to the updated guidelines on acute stroke management. Failure to achieve a drug …

Platelet function assays for the diagnosis of aspirin resistance

N Van Oosterom, M Barras, N Cottrell, R Bird - Platelets, 2022 - Taylor & Francis
Aspirin, an antiplatelet drug, is commonly used at low doses for numerous indications,
including prophylaxis of cardiovascular, neurovascular, and venous thromboembolic events …

Monitoring antiplatelet therapy: where are we now?

R Marcucci, M Berteotti, F Gragnano… - Journal of …, 2023 - journals.lww.com
Single antiplatelet therapy represents the cornerstone of thrombosis prevention in
atherosclerotic cardiovascular disease. Dual antiplatelet therapy (DAPT), consisting of …

Safety and efficacy of dual antiplatelet pretreatment in patients with ischemic stroke treated with IV thrombolysis: a systematic review and meta-analysis

K Malhotra, AH Katsanos, N Goyal, N Ahmed, D Strbian… - Neurology, 2020 - neurology.org
Objective Conflicting data exist on the safety and efficacy of IV thrombolysis (IVT) in patients
with acute ischemic stroke (AIS) receiving dual antiplatelet pretreatment (DAPP). The aim of …

High on-clopidogrel platelet reactivity in ischaemic stroke or transient ischaemic attack: systematic review and meta-analysis

V Alakbarzade, X Huang, IC Ster, M McEntagart… - Journal of Stroke and …, 2020 - Elsevier
Objectives To assess the prevalence of high on-clopidogrel platelet reactivity (HCPR) in
patients with ischaemic stroke or transient ischaemic attack (IS/TIA), their outcome and …

Platelet function/reactivity testing and prediction of risk of recurrent vascular events and outcomes after TIA or ischaemic stroke: systematic review and meta-analysis

ST Lim, V Thijs, SJX Murphy, I Fernandez-Cadenas… - Journal of …, 2020 - Springer
Background The prevalence of ex vivo 'high on-treatment platelet reactivity (HTPR)'and its
relationship with recurrent vascular events/outcomes in patients with ischaemic …